Dubois C, Adriaenssens T, Annemans L, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium. Acta Cardiol. 2023; in press.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43 (7): 561–632. doi: 10.1093/eurheartj/ehab395.
Barbato E, Noc M, Baumbach A, et al. Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) atlas project. Eur Heart J. 202; 41 (27): 2579–2588. doi: 10.1093/eurheartj/ehaa475.
Mylotte D, Osnabrugge TLJ, Martucci G, et al. Adoption of transcatheter aortic valve implantation in Western Europe. Interv Cardiol. 2011; 9 (1): 37–40. doi: 10.15420/icr.2011.9.1.37.
Auffret V, Lefevre T, Van Belle E, et al. Temporal trends in transcatheter aortic valve replacement in France: France 2 to France TAVI. J Am Coll Cardiol. 2017; 70 (1): 42–55. doi: 10.1016/j.jacc.2017.04.053.
Mauri V, Abdel-Wahab M, Bleiziffer S, et al. Temporal trends of TAVI treatment characteristics in high volume centers in Germany 2013-2020. Clin Res Cardiol. 2022; 111 (8): 881–888. doi: 10.1007/s00392-021-01963-3.
Implantaten en invasieve medische hulpmiddelen: Lijst van de verstrekkingen en nominatieve lijsten van de individuele hulpmiddelen. Rijksinstituut voor ziekte- en invaliditeitsverzekering. https://www.riziv.fgov.be/nl/professionals/individuelezorgverleners/verstrekkers-van-implantaten/Paginas/implantaten-lijst-verstrekkingen-nominatieve.aspx.
Standpunt transcatheter aortaklepimplantatie (TAVI) bij patiënten met symptomatische ernstige aortaklepstenose (update). https://www.zorginstituutnederland.nl/publicaties/standpunten/2020/09/30/standpunt-tavi-bij-ernstige-aortaklepstenose.
Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996; 276 (14): 1172–1177.
Gilard M, Eltchaninoff H, Iung B, et al. Cost effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value Health. 2022; 25 (4): 605–613. doi: 10.1016/j.jval.2021.10.003.
Mennini FS, Meucci F, Pesarini G, et al. Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients. Int J Cardiol. 2022; 357: 26–32. doi: 10.1016/j.ijcard.2022.03.034.
Kuck KH, Leidl R, Frankenstein L, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation versus surgical aortic valve replacement in German severe aortic stenosis patients at low surgical mortality risk. Adv Ther. 2023; 40 (3): 1031–1046. doi: 10.1007/s12325-022-02392-y.
Tchétché D, de Gennes CD, Cormerais Q, et al. Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial. Eur J Health Econ. 2023. doi: 10.1007/s10198-023-01590-x.
NICE: Cost-utility analysis: Transcatheter intervention for patients who have operable aortic stenosis NICE guideline NG208. 2021. https://www.nice.org.uk/guidance/ng208/evidence/tavi-economic-analysis-pdf-10890776557.
Health Information & Quality Authority (HIQA), Ireland. https://www.hiqa.ie/sites/default/files/2019-12/TAVI_HTA.pdf.
NIPH: Norwegian Institute of Public Health (NIPH). https://www.fhi.no/en/publ/2021/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups/.
Gupta N, Verma R, Dhiman RK, et al. Cost-Effectiveness analysis and decision modelling: a tutorial for clinicians. J Clin Exp Hepatol. 2020; 10 (2): 177–184. doi: 10.1016/j.jceh.2019.11.001.
Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021; 77 (9): 1149–1161. doi: 10.1016/j.jacc.2020.12.052.
Forrest JK, Deeb GM, Yakubov SJ, et al. 4-Year outcomes of patients with aortic stenosis in the evolut low risk trial. J Am Coll Cardiol. 2023:S0735-1097(23)07628-3. doi: 10.1016/j.jacc.2023.09.813.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023. doi: 10.1056/NEJMoa2307447.
Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021; 42 (30): 2912–2919. doi: 10.1093/eurheartj/ehab375.
